abemaciclib,ribociclib
eli lilly,novartis
['breast']
issues with adjuvant cdk inhibitors trial in early breast cancer. longer follow up is much needed. os and efficacy beyond treatment period needs to be seen #asco23 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists